Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation.
A randomized, prospective comparison of OKT3 vs. ALG (University of Minnesota) was performed in patients who had acute renal failure after a cadaver renal transplantation. Criteria for admission to the study were oliguria or increasing serum creatinine in the first 12 hr after renal transplantation. ALG or OKT3 was administered after randomization beginning 12-36 hours posttransplantation. There were no significant differences in age, sex, original disease, ischemia time, or HLA matching between groups. Graft survivals at 1 and 6 months were 84% and 84%, respectively for the ALG group. One- and 6-month graft survival for the OKT3 group was 88% and 84%, respectively. These differences were not statistically significant. The number of rejection episodes and the number of patients with rejection episodes were greater, and the time to first rejection was shorter in the OKT3 group compared with the ALG group, although none of these differences reached statistical significance. There were significantly less side effects in the ALG group compared with the OKT3 group (P less than .05). The greatest reductions in side effects were in fever and hypotension. Patients were monitored with flow cytometry analysis measuring the number of CD2 (T11) and CD3 (T3) cells to adjust the dose of both OKT3 and ALG. Starting doses were 10 mg/kg/day of ALG and 5 mg/day of OKT3. There were no significant differences in the incidence of infections (viral or bacterial) between the two groups. There were no rejection episodes during the prophylactic therapy with either ALG or OKT3. In summary, both ALG and OKT3 provided effective prophylaxis for patients with acute renal failure after renal transplantation. OKT3 was associated with a statistically significant increase in incidence of symptomatic side effects.
Steinmuller
D R
DR
Department of Hypertension/Nephrology, Cleveland Clinic Foundation, Ohio 44195-5042.
Hayes
J M
JM
Novick
A C
AC
Streem
S B
SB
Hodge
E
E
Slavis
S
S
Martinez
A
A
Graneto
D
D
Pearce
G
G
D058186:Acute Kidney Injury / Q000517:prevention & control*; D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000961:Antilymphocyte Serum / Q000494:pharmacology*; D001379:Azathioprine / Q000627:therapeutic use; D018801:CD2 Antigens; D017252:CD3 Complex; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000627:therapeutic use; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011241:Prednisone / Q000627:therapeutic use; D011446:Prospective Studies; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D011971:Receptors, Immunologic / Q000032:analysis
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000961:Antilymphocyte Serum; D018801:CD2 Antigens; D017252:CD3 Complex; D003524:Cyclosporins; D007074:Immunoglobulin G; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone